Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy

Leukemia and Lymphoma

Volumn 54, Issue 11, 2013, Pages 2452-2457

  Zhu, Hong Hu ^a   Jiang, Hao ^a   Jiang, Bin ^a   Lu, Jin ^a   Jiang, Qian ^a   Bao, Li ^a   Zhang, Xiao Hui ^a   Qin, Ya Zhen ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Acute myeloid leukemia; CAG regimen; Complete remission

Indexed keywords

ACLARUBICIN; ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HUMAN; INDUCTION CHEMOTHERAPY; INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT;

ACLARUBICIN; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84885616334     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.776679     Document Type: Article

References (29)

1. DohnerH, EsteyEH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults:Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
2. Burnett A, Wetzler M, Lowenb erg B. Therapeutic advances in acute myeloid leukemia. J Gun Oncol 2011;29:487-494.
3. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia:Results of the MRC AML12 trial. J Clin Oncol 2010;28: 586-595.
4. Fernandez HF, SunZ, YaoX, et al, Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-1259.
5. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: Results of the MRC AML15 trial. Blood 2009;1 14(Suppl. 1): Abstract 200.
6. Mandelli F, Vignetti M, Suciu 5, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: The EORTC and GIMEMA Groups Study AML-10. J Clin Oncol2009;27:5397-5403.
7. Schlenk RF, Benner A, Hartmann F, et al. Risk adapted post-remission therapy in acute myeloid leukemia: Results of the German Multicenter AML HD93 treatment trial. Leukemia 2003;17:1521-1528.
8. T?Cern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: Data from the German AML cooperative group (AM-LCG) 1992 trial. Blood 2003;101:64-70.
9. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. Br J Haematol 1999;107:69-79.
10. ICern W, Aul C, Maschmeyer G, et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison. Leukemia 1998;12:1049-1055.
11. Ravandi F, Cortes J, Fader 5, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010;116: 5818-5823.
12. Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Tnt J Hematol 2000;71:238-244.
13. Lofgren C, Paul C, Astrom M, et al. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: A Swedish multicentre randomized trial. Br Haematol 2004;124:474-480.
14. EsteyE, Thall PF, T(antarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-1nfusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSE Blood 1992;79:2246-2255.
15. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients: Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998;91: 2722-2730.
16. Qian SX, Li JY, Tian T, et al. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia. Leuk Res 2007;31:1383-1388.
17. Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte -macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: A trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21: 453-461.
18. Lowenberg B, Van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003;349: 743-752.
19. Amadori 5, Suciu 5, Jehn U, et al. Use of glycosylated human recombinant G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: Final results of AML-13, a randomized phase-3 study. Blood 2005; 106:27-34.
20. Thomas X, Raffoux E, Renneville A, et al. Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:1725-1732.
21. Wei GQ, Ni WM, Chiao JW, et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 2011;4:46.
22. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-1dentical sibling transplantation. Blood 2006;107:3065-3073.
23. Chen YH, HuangXJ, Xu LP, et al. A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors. Zhonghua Nei Ke Za Zhi 2006;45:624-627.
24. FernandezHF,SunZ,YaoX, etal.Anthracyclinedoseintensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-1259.
25. Hann TM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council?s 1OthAML trial (MRC AML1O). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311-2318.
26. Miyauchi L Kelleher CA, Wang C, et al. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989;73:1272-1278.
27. Tnatomi Y, Toyama K, Clark SC, et al. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994;54:455-462.
28. Graf M, Hecht K, Reif 5, et al. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): Implications for future therapeutical strategies. Eur J Haematol 2004; 72:89-106.
29. Kutlay S, Beksac M, Dalva K, et al. The detection of flow cytometric G-CSF receptor expression and its effect on therapy in acute myeloid leukemia. Leuk Lymphoma 2003;44:791-795.